Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 94 | SFEBES2023 | Next issue

Society for Endocrinology BES 2023

Glasgow, UK
13 Nov 2023 - 15 Nov 2023

Card image cap
SfE BES is the UK's leading endocrinology meeting. It will return to Glasgow in 2023.

Poster Presentations

Endocrine Cancer and Late Effects

ea0094p302 | Endocrine Cancer and Late Effects | SFEBES2023

Thyroid function in patients receiving immune checkpoint inhibitors: a large real-world cohort study

Kennedy Oliver , Hoong Ho Jan , Monaghan Phillip , Lorigan Paul , Adam Safwaan

Objective: This study aimed to characterise the relationship between immune checkpoint inhibitors (ICIs), which are commonly used to treat cancer, and thyroid dysfunction in terms of the proportions affected, timing of onset, sequalae and risk factors.Design: Retrospective cohort studyMethods: Patients with normal baseline thyroid function who received an ICI were included. Proport...

ea0094p46 | Endocrine Cancer and Late Effects | SFEBES2023

Utility of recumbent, age-adjusted plasma normetadrenaline thresholds to guide identification of small SDHB-deficient paragangliomas in clinical practice

Anjum Suzana , Gazet Marianne , Hameeduddin Ayshea , Akker Scott , Lim Eugenie

Background: Plasma normetanephrine levels are an annual screening tool for detecting paragangliomas in SDHB mutation carriers. Sensitivity is increased when patients are fasting and recumbent prior to phlebotomy, to allow use of age-adjusted reference ranges rather than the 1180 pmol/l upper limit for ambulatory patients of any age. We present our clinic’s results of samples taken after 30 minutes of recumbency to determine if applying age-adjusted ranges...

ea0094p47 | Endocrine Cancer and Late Effects | SFEBES2023

In silico-based analysis of differentially expressed miRNAs involved in the ovarian cancer

T. Mohammed Bushra , Taha Mohammed Zainab

Ovarian cancer is one of the major cause of death among women worldwide with high incidence. Ovarian cancer can be categorized into epithelial, non-epithelial (germ cell and sex cord-stromal cell), and metastatic (usually develop from surrounding cancerous organs). Recently, several approaches have been studied to control ovarian cancer at the transcriptional or post-transcriptional levels using small non coding RNAs including microRNAs. We carried out a meta-analysis of previ...

ea0094p48 | Endocrine Cancer and Late Effects | SFEBES2023

MicroRNA drivers of resistance to androgen deprivation therapy in prostate cancer

Saunders Philippa , Fletcher Claire

Introduction: Prostate cancer is the most prevalent malignancy affecting Western males. Initially an androgen-dependent disease, androgens bind to the androgen receptor and drive expression of genes that promote proliferation and evasion of apoptosis. Although advanced disease involves reduced androgen dependence, androgen receptor signalling remains a key driver of growth. Androgen deprivation therapy (ADT) is first line, but resistance inevitably develops. A...

ea0094p49 | Endocrine Cancer and Late Effects | SFEBES2023

Neuroendocrine cancer: An ideal patient pathway

Jervis Nikie , Bouvier-Ellis Catherine

Neuroendocrine cancers represent the tenth most prevalent type of cancer in England. However, people with neuroendocrine cancer currently face significant inequities throughout the entire care pathway – from suspected cancer to follow-up care. Despite expert clinical guidelines, there is no currently available national Neuroendocrine Cancer Patient Referral and Care Pathway. Guiding principles of optimal patient pathways include the promotion of earlier, accurate diagnosi...

ea0094p50 | Endocrine Cancer and Late Effects | SFEBES2023

Survival rates in metastatic gastroenteropancreatic neoplasms after multidisciplinary approach

Trifanescu Raluca , Iftimie Madalina , Mohora Alexandra , Toma Iustin , Trifanescu Oana , Poiana Catalina

Background: Prevalence of neuroendocrine neoplasms is increasing and multidisciplinary approach is mandatory. This study aimed to assess the outcome of patients with gastroenteropancreatic neoplasms (GEP NEN) presenting in a tertiary endocrine center.Methods: Retrospective study on 36 patients (16 M/20 F) with pathology confirmed GEP NEN, aged 51.9 ± 12.7 years. Serum chromogranin A, serotonin, neuron-specific enolase...

ea0094p198 | Endocrine Cancer and Late Effects | SFEBES2023

Evaluation of a national genetic testing service for monogenic endocrine disease in Scotland; enforcement of referral criteria may result in missed opportunities for genetic diagnosis

Ahmed Sufia , McLean Joanne , Berg Jonathan , Goudie David , Newey Paul

Background: Establishing a genetic diagnosis in patients presenting with potential monogenic endocrine disorders can provide benefits for the individual and wider family. Next-generation sequencing (NGS) gene panels provide a time- and cost-efficient platform for testing. A Scottish NGS endocrine testing platform, comprising 30 genes (11 individual panels), was established in 2018. A national genomic test-directory provides eligibility criteria for testing, bu...

ea0094p199 | Endocrine Cancer and Late Effects | SFEBES2023

Stroke Risk in Childhood, Adolescent, and Young Adult (CAYA) Cancer Survivors who Received Cranial Radiotherapy

Ruiheng Chen Lillian , Spurgeon Laura , Smith Christopher , Adam Safwaan , Emily Higham Claire

Background: CAYA cancer survivors who received cranial radiotherapy have an increased risk of stroke. Traditional cardiovascular disease (CVD) risk factors likely contribute, but there are no guidelines for management of stroke risk in this population. It is unclear how general CVD risk calculators (QRISK3, Framingham Risk Score) compare to specific cancer survivors scores such as the Childhood Cancer Survivors Study Stroke Risk Calculator (CCSS).<p class=...

ea0094p200 | Endocrine Cancer and Late Effects | SFEBES2023

SURvey of Surgeon’s and Physician’s experiences of GEnetic testing in patients with Familial Endocrine Syndromes: SurGe in UK and Abroad

de Jong Mechteld , Parameswaran Rajeev , Kurzawinski Tom

Introduction: Genetic testing for Familial Endocrine Syndromes has an important role in diagnosis, timing/extent of surgery, and follow-up. Our survey explored experiences and attitudes towards genetic testing in the UK and Abroad.Methods: Attendees of 2022 Conferences of ESES, BSPED, SfE, BAETS and AsianAES were asked to participate in an online survey (31 questions on demographics; genetic testing availability and expe...

ea0094p201 | Endocrine Cancer and Late Effects | SFEBES2023

Paraganglioma syndromes data from a single centre

Tavoukjian Vera , Bano Gul , Alsters Suzanne

Paraganglioma syndromes (PGL) encompass a diverse group of rare neuroendocrine tumours that are characterised by hereditary predisposition and present unique diagnostic and management challenges. We performed an audit to assess the prevalence, presentation, testing, diagnosis, and treatment of these patients. We did a retrospective analysis of the genetic database and medical records of PGL patients diagnosed and managed at our hospital up till April 2023. A total of 119 cases...

ea0094p202 | Endocrine Cancer and Late Effects | SFEBES2023

Probing the functional role of peptidylglycine alpha-amidating monooxygenase (PAM) in the maintenance and transition towards neuroendocrine prostate cancer

Taracatac Paolo , Bagamasbad Pia

Castration-resistant prostate cancer (CRPC) is an androgen-independent subtype of prostate cancer (PCa) that develops in response to androgen deprivation therapy (ADT). In some advanced CRPC cases, tumors can develop the neuroendocrine (NE) phenotype and progress towards an aggressive PCa subtype known as treatment-induced NE PCa (NEPC), which is characterized by an increase in the population of NE cells that secrete neuropeptides promoting cancer progression. A key player in ...

ea0094p203 | Endocrine Cancer and Late Effects | SFEBES2023

Selective use of mutational analysis helps with diagnostic challenge in hypercalcaemia

Latif Wajeeha , Ali Asif

A 34-year-old was referred for a second opinion regarding his incidental mild hypercalcemia ranging between 2.56 mmol/l and 2.88 mmol/l, with a corresponding PTH ranging between of 3.3 pmol/l and 6.8 pmol/l (laboratory reference range 1.3-9.3 pmol/l). He did not have a history of renal calculi or fractures. He reported chronic recurrent diarrhoea, weight loss, low mood and chronic headache. There was no known family history of calcium disorders. His examination did not reveal ...

ea0094p336 | Endocrine Cancer and Late Effects | SFEBES2023

Ectopic ACTH-dependant Cushing’s syndrome in MEN2A and metastatic medullary thyroid carcinoma: Challenges beyond Diagnosis

Bahl Suhani , Khaliq Hamdan Mohd , Smeeton Fiona , MacLean Jillian

Introduction: Multiple endocrine neoplasia, type 2A (MEN 2A) is a hereditary syndrome characterized by medullary carcinoma of the thyroid, pheochromocytoma, parathyroid hyperplasia or adenomas due to mutation in RET oncogene on chromosome 10. Complications can occur as a result of ectopic ACTH causing Cushings syndrome. We present here a case initially presenting to hospital with worsening shortness of breath on a background of metastatic medullary thyroid can...

ea0094p337 | Endocrine Cancer and Late Effects | SFEBES2023

Pilot study of liquid biopsy in paragangliomas: a feasible alternative to tissue biopsy in inoperable and multifocal lesions?

White Gemma , Quinn Mark , Carroll Paul , Velusamy Anand , Thakali Sonu , J. Oakey Rebecca , Izatt Louise , Hassan Fahim-UI

Background: Phaeochromocytoma and paraganglioma (PPGL) are highly heritable, with 30-40% due to a germline pathogenic variant. An additional 40% of tumours will harbour a somatic variant. Understanding the variant status of a tumour enables molecular classification. Liquid biopsy offers a novel approach to non-invasive diagnostics by harnessing the ability to detect small amounts of circulating-free DNA (cfDNA) and performing genomic sequencing. There are few ...

ea0094p338 | Endocrine Cancer and Late Effects | SFEBES2023

Papillary thyroid cancer occuring in thyroglossal duct cyst- a rare presentation

Sathyanarayan Sheela , Madan Arina , Salema Valmiki , Velusamy Anand , Anandappa Samanth , Ul-Hassan Fahim , Hubbard Jonathan

Thyroglossal duct cysts are the most frequently occurring congenital cervical anomaly, however the development of Papillary Thyroid Cancer (PTC) in these are very rare, with an incidence around 1%. We present two cases of PTC identified in thyroglossal duct cysts from our services. A 26-year-old lady with a 1-year history of midline neck swelling, was investigated with a neck ultrasound which showed a 2.8cm septated thyroglossal duct cyst and U2 thyroid cyst. She underwent a F...